Arvell Jones

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

Retrieved on: 
Wednesday, June 21, 2023
Columbia University, Seizure, Yale University, Tourette syndrome, Stuttering, University, Therapy, Central nervous system, Tic, Culture, Sofinnova, Physician, Trigeminal neuralgia, INVU (album), USD, CNS, TS, Axovant Sciences, Science, Pain, TSC, Columbia University Vagelos College of Physicians and Surgeons, Polaris Partners, Patient, Arvell Jones, Brown University, Surgeon, Faculty, Knowledge, Growth, Columbia University College of Dental Medicine, COFD, Psychiatry, Pfizer, Pharmaceutical industry, European, Noema

BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.

Key Points: 
  • BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.
  • “We are very excited that Ilise will be stepping into the CEO role at Noema Pharma.
  • Ilise has the expertise and experience to lead Noema as the Company enters its next phase of growth,” said Jeffrey Jonas, M.D., Chairman of Noema Pharma’s Board of Directors.
  • “I am thrilled to assume this leadership position with Noema Pharma at such a critical phase in the Company’s growth,” said Dr. Lombardo.

Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 12, 2021
Gene, Society, SIOX, Program, Annual general meeting, PARK, Cerebrospinal fluid, Domestication, GMP, GLOBE, Arvell Jones, Q3, IMPD, Organization, Security (finance), FDA, Type 2, Oxford BioMedica, COVID-19, Safety, Private Securities Litigation Reform Act, Industry, Hand, NASDAQ, Certification, Type, Food, NEW, Sale, Clinical trial, GM1, CNS, MHRA, Sio, U.S. Securities and Exchange Commission, Tay–Sachs disease, Company, 2012 Giro d'Italia, Stage 1 to Stage 11, AAV, Cell, Imagination, RESEARCH, Infant, Research, Neurodegeneration, Sandhoff disease, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CSF, Stage 2, American Society of Gene and Cell Therapy, Patient, Completeness, Adult, Cryptocurrency, Pharmaceutical industry, Medical device

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided a corporate update and financial results for its fiscal first quarter ended June 30, 2021.

Key Points: 
  • The Company continues to collect information from additional Type II patients for potential enrollment in Stage 2 of the trial.
  • For the fiscal first quarter ended June 30, 2021, research and development expenses were $8.1 million, an increase of $2.9 million compared to the fiscal first quarter ended June 30, 2020.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Sio expected.